DermTech, Inc. (DMTK): Price and Financial Metrics
DMTK Price/Volume Stats
| Current price | $2.76 | 52-week high | $8.93 |
| Prev. close | $2.82 | 52-week low | $1.55 |
| Day low | $2.73 | Volume | 26,719 |
| Day high | $2.87 | Avg. volume | 582,311 |
| 50-day MA | $3.12 | Dividend yield | N/A |
| 200-day MA | $3.58 | Market Cap | 85.81M |
DMTK Stock Price Chart Interactive Chart >
DMTK POWR Grades
- Value is the dimension where DMTK ranks best; there it ranks ahead of 47.87% of US stocks.
- The strongest trend for DMTK is in Growth, which has been heading up over the past 179 days.
- DMTK's current lowest rank is in the Sentiment metric (where it is better than 0.84% of US stocks).
DMTK Stock Summary
- DERMTECH INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 15.14% of US listed stocks.
- With a year-over-year growth in debt of 138.52%, DERMTECH INC's debt growth rate surpasses 90.51% of about US stocks.
- In terms of volatility of its share price, DMTK is more volatile than 87% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to DERMTECH INC, a group of peers worth examining would be BMRA, WKME, LUNG, BSGM, and NTRB.
- Visit DMTK's SEC page to see the company's official filings. To visit the company's web site, go to www.dermtech.com.
DMTK Valuation Summary
- In comparison to the median Healthcare stock, DMTK's price/earnings ratio is 102.9% lower, now standing at -0.7.
- Over the past 72 months, DMTK's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for DMTK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DMTK | 2023-05-23 | 5.5 | 0.7 | -0.7 | -0.7 |
| DMTK | 2023-05-22 | 5.0 | 0.7 | -0.6 | -0.6 |
| DMTK | 2023-05-19 | 5.0 | 0.7 | -0.6 | -0.6 |
| DMTK | 2023-05-18 | 5.4 | 0.7 | -0.7 | -0.7 |
| DMTK | 2023-05-17 | 5.6 | 0.7 | -0.7 | -0.7 |
| DMTK | 2023-05-16 | 5.1 | 0.7 | -0.6 | -0.7 |
DMTK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DMTK has a Quality Grade of F, ranking ahead of 1.78% of graded US stocks.
- DMTK's asset turnover comes in at 0.055 -- ranking 76th of 81 Healthcare stocks.
- LFMD, AHCO, and RHE are the stocks whose asset turnover ratios are most correlated with DMTK.
The table below shows DMTK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.055 | 0.128 | -1.299 |
| 2021-03-31 | 0.060 | 0.010 | -1.492 |
| 2020-12-31 | 0.089 | -0.016 | -1.875 |
| 2020-09-30 | 0.101 | -0.020 | -3.873 |
| 2020-06-30 | 0.102 | -0.017 | 12.100 |
| 2020-03-31 | 0.117 | 0.141 | -20.696 |
DMTK Price Target
For more insight on analysts targets of DMTK, see our DMTK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $62.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
DermTech, Inc. (DMTK) Company Bio
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Latest DMTK News From Around the Web
Below are the latest news stories about DERMTECH INC that investors may wish to consider to help them evaluate DMTK as an investment opportunity.
DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)SAN DIEGO, June 07, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a g |
DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)SAN DIEGO, June 02, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to eight new employees of restricted stock units representing the contingent right to receive up to an aggregate of 28,500 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The restricted stock units were approved by DermTech’ |
DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)SAN DIEGO, May 31, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the DermTech Melanoma Test (DMT) has tested more than 200,000 suspicious pigmented lesions. The DMT uses non-invasive Smart Stickers™ to test for select genomic markers associated with melanoma, one of the deadliest forms of skin cancer. With a negative predictive value of over 99 percent, the test rules out |
DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT)SAN DIEGO, May 11, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced agreements with a Blues plan in South Carolina and the United Mine Workers of America Health and Retirement Funds ("UMWA Funds"). The contracts, which are both effective April 1, 2023, enhance access to the foundational assay of the DermTech Melanoma Test ("DMT") for the approximately 1.7 million members of the B |
DermTech, Inc. (NASDAQ:DMTK) Analysts Just Slashed This Year's Revenue Estimates By 16%One thing we could say about the analysts on DermTech, Inc. ( NASDAQ:DMTK ) - they aren't optimistic, having just made... |
DMTK Price Returns
| 1-mo | 5.34% |
| 3-mo | -19.30% |
| 6-mo | 24.89% |
| 1-year | -53.69% |
| 3-year | -79.37% |
| 5-year | N/A |
| YTD | 55.93% |
| 2022 | -88.80% |
| 2021 | -51.29% |
| 2020 | 161.61% |
| 2019 | -39.28% |
| 2018 | N/A |
Loading social stream, please wait...